Agreement brings expanded Biologics to in-vitro Diagnostics Industry

EUCODIS Bioscience, specialists in engineering and developing enzymes for pharma, biotech and applied markets has been acquired by Biosynth Carbosynth, a supplier of critical biological materials to the life science industry.  Having already worked together for a number of years, the agreement broadens Biosynth’s biological products and its custom services offerings in enzymes and chemical syntheses, to enable novel biocatalytic synthesis routes for small molecules.

The expanded range of enzymes, antibodies, antigens, plasma along with epitope mapping , complements  the biological materials supplied by Biosynth via its Aalto Bio Reagents subsidiary. As part of the Biosynth group, EUCODIS will continue to provide state of the art services with the added benefit that customers will now profit from the combined expertise of EUCODIS and Biosynth.

Dr. Urs Spitz, CEO and President of Biosynth, said, “Biosynth has collaborated with EUCODIS for many years, working on innovative enzyme projects for our customers and perfectly complementing our extensive expertise in enzyme substrate chemistry.  It makes absolute sense for EUCODIS to join us as a key part of our biological materials offering. We are delighted to be able to welcome the experienced and knowledgeable team we know so well into the Biosynth family.”

Dr. Jan Modregger, CEO of EUCODIS, added, “We are pleased to be joining Biosynth, a group with which we have enjoyed a longstanding relationship and which shares our science-led and customer focused philosophy. We are excited by the opportunity to grow even faster and to provide high performance enzymes and biocatalysis solutions to a global customer base.”

More information online